Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging
- PMID: 15467030
- DOI: 10.1093/jnci/djh275
Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging
Abstract
Background: The recently revised American Joint Committee on Cancer (AJCC) sixth edition cancer staging system increased the stratification within colon cancer stages II and III defined by the AJCC fifth edition system. Using nationally representative Surveillance, Epidemiology, and End Results (SEER) data, we compared survival rates associated with colon cancer stages defined according to both AJCC systems.
Methods: Using SEER data (from January 1, 1991, through December 31, 2000), we identified 119,363 patients with colon adenocarcinoma and included all patients in two analyses by stages defined by AJCC fifth and sixth edition systems. Tumors were stratified by SEER's "extent of disease" and "number of positive [lymph] nodes" coding schemes. Kaplan-Meier analyses were used to compare overall and stage-specific 5-year survival. All statistical tests were two-sided.
Results: Overall 5-year survival was 65.2%. According to stages defined by the AJCC fifth edition system, 5-year stage-specific survivals were 93.2% for stage I, 82.5% for stage II, 59.5% for stage III, and 8.1% for stage IV. According to stages defined by the AJCC sixth edition system, 5-year stage-specific survivals were 93.2% for stage I, 84.7% for stage IIa, 72.2% for stage IIb, 83.4% for stage IIIa, 64.1% for stage IIIb, 44.3% for stage IIIc, and 8.1% for stage IV. Under the sixth edition system, 5-year survival was statistically significantly better for patients with stage IIIa colon cancer (83.4%) than for patients with stage IIb disease (72.2%) (P<.001).
Conclusions: The AJCC sixth edition system for colon cancer stratifies survival more distinctly than the fifth edition system by providing more substages. The association of stage IIIa colon cancer with statistically significantly better survival than stage IIb in the new system may reflect current clinical practice, in which stage III patients receive chemotherapy but stage II patients generally do not.
Comment in
-
Outcome prediction and the future of the TNM staging system.J Natl Cancer Inst. 2004 Oct 6;96(19):1408-9. doi: 10.1093/jnci/djh293. J Natl Cancer Inst. 2004. PMID: 15467022 No abstract available.
-
Re: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging.J Natl Cancer Inst. 2005 Mar 16;97(6):463-4; author reply 464-5. doi: 10.1093/jnci/dji080. J Natl Cancer Inst. 2005. PMID: 15770013 No abstract available.
-
Re: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging.J Natl Cancer Inst. 2005 Nov 16;97(22):1705-6; author reply 1706-7. doi: 10.1093/jnci/dji383. J Natl Cancer Inst. 2005. PMID: 16288127 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources